Constructing a better binding peptide for drug delivery targeting the interleukin-4 receptor
Autor: | Xue-Di Bai, Yi-Hui Chen, Fu-Jun Wang, Jian Zhao, Fu Longyun, Xue-Wei Cao |
---|---|
Rok vydání: | 2020 |
Předmět: |
Trichosanthin
Tumour targeting Pharmaceutical Science 02 engineering and technology 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Cell Line Tumor Interleukin-4 receptor Humans Medicine Interleukin 4 Drug Carriers business.industry Interleukins 021001 nanoscience & nanotechnology Binding peptide Antineoplastic Agents Phytogenic Receptors Interleukin-4 Tumour therapy 030220 oncology & carcinogenesis Drug delivery Cancer research Peptides 0210 nano-technology business Drug carrier Plasmids Protein Binding |
Zdroj: | Journal of Drug Targeting. 28:970-981 |
ISSN: | 1029-2330 1061-186X |
Popis: | Targeted delivery of antitumor drugs is especially important for tumour therapy. Tumour targeting peptides have been shown to be very effective drug carriers for tumour therapy. Interleukin-4 receptor (IL-4R) is overexpressed on the surface of various human solid tumours. To obtain a better targeting peptide, we first designed a novel targeting peptide derived from interleukin-4 (IL-4), ILBP-b. ILBP-b contains the key high-affinity binding residue E9 of IL-4 to IL-4R. Compared with a reported targeting peptide ILBP-a (containing another key high affinity residue R88), ILBP-b was proved to be a better targeting peptide by the fluorescence experiments. Then, we further fused ILBP-b and ILBP-a to increase the multisite-binding ability of ILBP-b and got a better targeting peptide ILBP-ba. ILBP-ba showed a stronger preferential binding ability to IL-4R high-expressing cells than ILBP-a and ILBP-b. Competitive binding experiments demonstrated ILBP-ba specifically targets IL-4R. By fusing ILBP-ba with drug protein trichosanthin (TCS), in vitro drug carrying experiments showed that ILBP-ba could specifically enhance the killing effect of TCS on IL-4R high-expressing tumour cells (more than 10 folds). These results indicated that ILBP-ba has great potential for drug delivery applications targeting IL-4R and will be beneficial for the development of tumour therapeutic agents. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |